Qiagen (NYSE:QGEN) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Qiagen (NYSE:QGEN) in a research note published on Thursday, The Fly reports. The brokerage issued a hold rating and a $33.00 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. Goldman Sachs Group reaffirmed a buy rating on shares of Qiagen in a research note on Thursday, August 1st. Evercore ISI raised shares of Qiagen from an in-line rating to an outperform rating in a research note on Thursday. Piper Jaffray Companies decreased their price target on shares of Qiagen from $36.00 to $31.00 and set a neutral rating on the stock in a research note on Tuesday, October 8th. Kepler Capital Markets raised shares of Qiagen from a reduce rating to a hold rating in a research note on Thursday. Finally, Barclays cut shares of Qiagen from an overweight rating to an equal weight rating and set a $32.00 price target on the stock. in a research note on Tuesday, October 8th. Ten equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $35.38.

Shares of Qiagen stock traded up $3.28 during mid-day trading on Thursday, hitting $40.56. 8,251,151 shares of the stock were exchanged, compared to its average volume of 1,395,547. Qiagen has a twelve month low of $25.04 and a twelve month high of $41.55. The stock has a market capitalization of $8.46 billion, a price-to-earnings ratio of 30.27, a price-to-earnings-growth ratio of 2.41 and a beta of 0.83. The company has a 50-day simple moving average of $30.26 and a 200 day simple moving average of $35.64. The company has a current ratio of 2.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.01. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The company had revenue of $382.70 million for the quarter, compared to analysts’ expectations of $382.98 million. During the same period last year, the company earned $0.35 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Equities research analysts forecast that Qiagen will post 1.4 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Private Capital Group LLC lifted its holdings in shares of Qiagen by 354.0% during the 2nd quarter. Private Capital Group LLC now owns 681 shares of the company’s stock worth $25,000 after acquiring an additional 531 shares during the period. Quest Capital Management Inc. ADV purchased a new position in shares of Qiagen during the 3rd quarter worth about $37,000. Huntington National Bank lifted its holdings in shares of Qiagen by 33.3% during the 3rd quarter. Huntington National Bank now owns 1,568 shares of the company’s stock worth $52,000 after acquiring an additional 392 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Qiagen by 1,244.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,385 shares of the company’s stock worth $56,000 after acquiring an additional 1,282 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Qiagen by 25.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,742 shares of the company’s stock worth $57,000 after acquiring an additional 357 shares during the period. Institutional investors and hedge funds own 61.95% of the company’s stock.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers

The Fly

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.